Board of Directors
James C. Ho, Ph.D. : Chairman
Dr. Ho has served as a member of our board of directors and as Chairman of our board of directors since Jan. 2015. He is also Chairman of SNSplus, Inc. and Hwa Sun Asset Management Corp. Dr. Ho has previously held several senior executive positions and served on the National Development Fund where he assisted the investment plans of many biotech companies. He received his master and Ph.D. in Economics at the University of Pittsburgh, PA, USA.
Grace Yeh, Ph.D. : Founder, President & Chief Executive Officer
Dr. Yeh worked in academic research in England and France, as well as in drug discovery and development at T Cell Sciences, CytoMed, LeukoSite, and Millennium Pharmaceuticals in Cambridge, MA, USA. She received her Ph.D. in Immunology at the Medical University of South Carolina, Charleston, SC, USA. She is a successful advocate in building and leading multi-disciplinary teams and in creating development strategies and resource plans to allow accelerated regulatory approval. Over the past thirteen years, under her leadership PharmaEngine has achieved many important milestones, including FDA approval of its new drug, ONIVYDE.
Jeffrey Suen : Legal Representative of TTY Biopharm Co., Ltd.
Mr. Suen is the advisor of TTY Biopharm Co., Ltd. and was previously the General Manager of China Development Industrial Bank, the largest VC for biotech. He received his MBA at Young America City State University in US.
Chuan Lin, Ph.D. : Legal Representative of TTY Biopharm Co., Ltd.
Dr. Lin is an Adjunct Professor of the Economics Department at National Taiwan University. He previously served as Minister of Finance and Chairman of VIS Corporation. He received his master in Public Finance at National Chengchi University, Taipei and his Ph.D. in Economics at University of Illinois, USA.
Li-Chen Lin : Legal Representative of the National Development Fund, Executive Yuan
Mrs. Lin is the Associate Director of the National Development Council and was previously the Chief Secretary of the Council for Economic Planning and Development, Executive Yuan. She received her master in Economics at National Taipei University, Taipei, Taiwan.
Po-Wu Gean, Ph.D.
Legal Representative of the National Development Fund, Executive Yuan
Dr. Gean is Vice Superintendent, NCKU College of Medicine and Chair Professor in Department of Pharmacology, National Cheng Kung University, Tainan. He received his Ph.D. in Pharmacology at University of Texas Medical Branch at Galveston, USA.
Wei-chen Tien, Ph.D.
Dr. Tien is an Adjunct Professor in Department of Life Sciences and Institute of Genome Sciences, National Yang-Ming University, Taipei. He also serves as an advisor for the Executive Yuan in Taiwan and on its audit committee for the biotech industry. He received his Ph.D. in Microbiology and Genetics at University of Kentucky, USA.
Fu-Shiow Yin, Ph.D. : Independent Director
Dr. Yin is an Independent Director of Pac-Link BioVenturesShe has been on the evaluation committee for biomedical projects in the government department(MOEA) for many years. She earned her Ph.D. in Biochemistry at Rutgers University, New Jersey, USA.
Frank Li-Sheng Chu : Independent Director
Mr. Chu is vVice General Manager of the Industry Academia Collaboration Office at Asia University, Taiwan. He is also an Independent Director for Wellpool Co., Ltd., and Yue Yuen Industrial (Holdings) Ltd. He received his master in Business Administration at National Taiwan University.
Dr. James C. Ho: Chairman
Dr. Ho is Chairman of Hwa Sun Asset Management Corp, has served as a member of our board of directors since June 2013,and as Chairman since January 2015. Dr. Ho has held senior executive positions and served as General Secretary at the National Development Fund for investing in a number of biotech companies. He received his master and Ph.D. in Economics at the University of Pittsburgh, PA, USA.
Dr. Grace Yeh: Founder, President & Chief Executive Officer
Dr. Yeh founded PharmaEngine, Inc. in Jan. 2003, and has served as President and Chief Executive Officer. She worked in academic research institutions in England and France, as well as in drug discovery and development at T Cell Sciences, CytoMed, LeukoSite, and Millennium Pharmaceuticals in Cambridge, MA, USA. She has been successful in building and leading multi-disciplinary teams and in creating development strategies and resource plans to allow accelerated regulatory approval. She received her Ph.D. in Immunology at the Medical University of South Carolina, Charleston, SC, USA.
Dr. Alain Herrera: Head, Corporate Development; Managing Director, PharmaEngine Europe Sarl
Dr. Herrera joined the Scientific Advisory Board of PharmaEngine in November 2008. He created the Foundation of Alain Oncology Consulting in November 2008 after heading for ten years the oncology business at sanofi-aventis where he was successively Vice President responsible for Global Oncology Business Strategy and Development (2007-2008) and Head of Global Oncology Franchise (1998-2007) and contributed to the worldwide registration of two products: oxaliplatin (ELOXATIN®) and rasburicase (FASTURTEC®/ELITEK®) as well as the gastric and head & neck indications for docetaxel (TAXOTERE®). He received his MD from Pitié-Salpétrière Hospital, Faculty of Medicine, Paris, France.
Dr. C. Hubert Chan: Vice President, Clinical and Regulatory Affairs
Dr. Chan joined PharmaEngine in February 2016. He is a board certified medical oncologist. In addition to clinical practice, he has involved in several global clinical trials. He conducted two investigator initiated trials while he was at National Health Research Institutes, Taiwan. His expertise will facilitate the success of clinical research, which is essential for the new drug development. He received his Ph.D. at University of Minnesota, USA and MD at Chung Shan Medical University, Taiwan.
Dr. Armand de Gramont: Vice President, Translational Science
Dr. de Gramont joined the Scientific Advisory Board since January 2012. He was trained at the Laboratory of Molecular and Cellular Biology, National Institutes of Health (NIH), USA. After returning to France, he became Chief Operating Officer & General Manager at AAREC Filia Research, Paris. Most recently, he was Head of the New Drugs Evaluation Laboratory, Lausanne University Hospital, Switzerland. His expertise is in the area of translational medicine in oncology. He received his Ph.D. in Cellular Biochemistry at Pierre et Marie Curie University, Paris, France.
C. H. Chang: Vice President, Finance & Administration
Mr. Chang joined PharmaEngine in February 2003. He is a certified public accountant (CPA) in Taiwan. He worked at TTY Biopharm as the Director of Stock Affairs Department, and MasterLink Securities and Sampo Securities for many years majored in IPOs in Taiwan. He received his Master degree of Accounting from National Taiwan University, Taiwan.
Peter Wu: Director, Marketing & Sales
Mr. Wu joined PharmaEngine in July 2004. He majored in marketing and sales of oncology products at Novartis (Taiwan) and Kirin (Taiwan), responsible for Glivec®, Aredia®, G-CSF and EPO. Mr. Wu received his Bachelor degree in Pharmacy, Taipei Medical University, Taiwan.